CHAMPIONS ONCOLOGY, INC. Lease, Cost
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Lease, Cost of $431.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. lease, cost for the quarter ending 2026-07-31 was $431.00K, a 10.40% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. lease, cost for the quarter ending 2026-04-30 was $467.00K, a 1.68% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. lease, cost for the quarter ending 2026-01-31 was $486.00K, a 2.53% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. lease, cost for the quarter ending 2025-10-31 was $486.00K, a 2.97% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. lease, cost for fiscal 2026 was $1.92M, a 1.48% increase from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. lease, cost for fiscal 2025 was $1.89M, a 2.66% increase from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. lease, cost for fiscal 2024 was $1.84M, a 7.03% increase from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. lease, cost for fiscal 2023 was $1.72M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-07-31 | $431.00K 10-Q · filed 2026-09-11 | $898.00K derived: sum of 2 quarters · filed 2026-09-11 | $1.38M derived: sum of 3 quarters · filed 2026-09-11 | $1.87M derived: sum of 4 quarters · filed 2026-09-11 |
| 2026-04-30 | $467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $953.00K derived: sum of 2 quarters · filed 2026-07-27 | $1.44M derived: sum of 3 quarters · filed 2026-07-27 | $1.92M 10-K · filed 2026-07-27 |
| 2026-01-31 | $486.00K 10-Q · filed 2026-03-12 | $972.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.45M 10-Q · filed 2026-03-12 | $1.93M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-10-31 | $486.00K 10-Q · filed 2025-12-15 | $965.00K 10-Q · filed 2025-12-15 | $1.44M derived: sum of 3 quarters · filed 2026-09-11 | $1.92M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-07-31 | $481.00K 10-Q · filed 2026-09-11 | $956.00K derived: sum of 2 quarters · filed 2026-09-11 | $1.43M derived: sum of 3 quarters · filed 2026-09-11 | $1.90M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-04-30 | $475.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $949.00K derived: sum of 2 quarters · filed 2026-07-27 | $1.42M derived: sum of 3 quarters · filed 2026-07-27 | $1.89M 10-K · filed 2026-07-27 |
| 2025-01-31 | $474.00K 10-Q · filed 2026-03-12 | $946.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.42M 10-Q · filed 2026-03-12 | $1.88M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-10-31 | $472.00K 10-Q · filed 2025-12-15 | $941.00K 10-Q · filed 2025-12-15 | $1.41M derived: sum of 3 quarters · filed 2025-12-15 | $1.87M derived: sum of 4 quarters · filed 2025-12-15 |
| 2024-07-31 | $469.00K 10-Q · filed 2025-09-15 | $934.00K derived: sum of 2 quarters · filed 2025-09-15 | $1.40M derived: sum of 3 quarters · filed 2025-09-15 | $1.86M derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | $465.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $927.00K derived: sum of 2 quarters · filed 2025-07-23 | $1.39M derived: sum of 3 quarters · filed 2025-07-23 | $1.84M 10-K · filed 2025-07-23 |
| 2024-01-31 | $462.00K 10-Q · filed 2025-03-17 | $922.00K derived: sum of 2 quarters · filed 2025-03-17 | $1.38M 10-Q · filed 2025-03-17 | |
| 2023-10-31 | $460.00K 10-Q · filed 2024-12-16 | $914.00K 10-Q · filed 2024-12-16 | ||
| 2023-07-31 | $456.00K 10-Q · filed 2024-09-13 | |||
| 2023-04-30 | $1.72M 10-K · filed 2024-07-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |